Harmony Biosciences Stock Forecast
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
HRMY analyst consensus
Consensus (11 analysts)
buy
Avg. price target
$47.64+18.27%
- Strong buy 2
- Buy 5
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Harmony Biosciences (2026-10-07), 7 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $47.64, with a high estimate of $70.00 and a low estimate of $30.00. The average target implies upside of 18.3% from the current price of $40.28.
The spread between the highest and lowest targets is 133.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for HRMY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 18% |
| Buy | 5 | 45% |
| Hold | 3 | 27% |
| Sell | 0 | 0% |
| Strong sell | 1 | 9% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | -25.52% |
| Average target | $47.64 | +18.27% |
| High target | $70.00 | +73.78% |